Crystal Pharmatech
Shreeya Jadhav, M.S., currently serves as a Research Scientist I at Crystal Pharmatech, a position held since January 2023. Prior experience includes work as a Graduate Research Assistant at Albany College of Pharmacy and Health Sciences from September 2021 to January 2023, and a role as a Management Trainee and Medical Writer at Docintosh from September 2019 to December 2020. Shreeya Jadhav also completed an internship at Merck in May 2018. Educational credentials include a Master of Science in Pharmaceutical Sciences from Albany College of Pharmacy and Health Sciences (2021-2022) and a Bachelor of Pharmacy from Vivekanand Education Society's College of Pharmacy in Mumbai (2015-2019).
Crystal Pharmatech
Established in 2010, Crystal Pharmatech is a specialized CRO/CDMO, excelling in crystal form and formulation services. Our exceptional track record includes supporting 1,000 clients and collaborating on over 2,000 compounds, showcasing our expertise in solid-state research, crystallization, pre-formulation, formulation development, and manufacturing. With a global presence encompassing three strategically located R&D centers in Suzhou (China), New Jersey (USA), and Toronto (Canada), we are powered by a skilled team of around 250 professionals. As a leader in both conventional and enabling formulation technologies, including amorphous solid dispersion, we take pride in our cGMP facilities, strictly adhering to the rigorous standards set by the FDA, EMA, and NMPA. Our integrated service encompasses the entire new drug development journey, from developability assessment and solid form screening to pre-formulation, formulation development, and CTM and commercial manufacturing. Introducing our pioneering Mol2Med program, designed to expedite small molecule lead compounds or preclinical candidates into Phase I and beyond, with unparalleled efficiency and precision. This 3-step First-Time-Right approach begins at the lead optimization/PCC stage: Step 1: Developability Assessment to guide API form selection and formulation design. Step 2: Solid form screening/selection and Preformulation. Step 3: Formulation development and CTM manufacturing, including packaging, labeling, and shipping to the clinical site. This innovative approach guarantees a robust API form and a scalable manufacturing process, culminating in a First-Time-Right formulation for Phase I. Streamlining the transition to future clinical studies upon Phase I success, our First-Time-Right approach sets the foundation for optimized drug development and success beyond.